
The director of the Movement Disorders Clinic at Houston Methodist Hospital outlined a stepwise approach for identifying, managing, and treating hallucinations in patients with Parkinson disease. [WATCH TIME: 3 minutes]
The director of the Movement Disorders Clinic at Houston Methodist Hospital outlined a stepwise approach for identifying, managing, and treating hallucinations in patients with Parkinson disease. [WATCH TIME: 3 minutes]
The director of the Movement Disorders Clinic at Houston Methodist Hospital discussed the distinct features, progression, and clinical implications of psychosis in Parkinson disease. [WATCH TIME: 4 minutes]
The expert panel reviews unmet needs in treatment and management of dyskinesia and shares advice for physicians treating patients with Parkinson disease.
Drs Fernando Pagan, Robert A. Hauser, and Daniel Kremens highlight existing and emerging surgical and pharmacological options for treatment of dyskinesia in Parkinson disease.
The expert neurology panel shares their clinical experience with different formulations of amantadine in management of dyskinesia in patients with Parkinson disease.
The expert panel reviews the safety profile of amantadine DR/ER and who may be an ideal patient for its use in patients with Parkinson disease experiencing dyskinesia.
The expert neurology panel discusses clinical trial data of amantadine-DR/ER in treatment of dyskinesia and OFF episodes in Parkinson disease.
Drs William G. Ondo and Rajesh Pahwa analyze the pharmacokinetics of different formulations of amantadine for treatment of dyskinesia in Parkinson disease.
Drs Rajesh Pahwa, Daniels Kremens and Fernando Pagan provide an overview of current treatment options for treatment of dyskinesia in patients with Parkinson’s Disease.
The expert panel highlights challenges in treatment of OFF episodes and dyskinesia together and long-term consequences of delaying treatment for dyskinesia in patients with Parkinson disease.
The expert panel shares strategies for accurate clinical diagnosis of dyskinesia in patients with Parkinson disease and discusses how dyskinesia may impact the quality of life.
The expert neurology panel examines risk factors for development of dyskinesia in patients with Parkinson disease.
Drs William G. Ondo and Robert A. Hauser discuss the understanding of pathophysiology and clinical features of dyskinesia in patients with Parkinson disease.
Drs Rajesh Pahwa and Daniel E. Kremens discuss challenges with Parkinson disease treatment and management of motor fluctuations, dyskinesia and OFF episodes in patients.
The expert panel discusses advances in formulations of carbidopa/levodopa and identification of OFF and ON time in patients with Parkinson disease.
Dr William G. Ondo provides an overview of available treatments and pharmacokinetic properties of different drugs for Parkinson Disease.
Expert neurologists provide insight on how to decide on an on-demand therapy for Parkinson’s disease and provide some general advice.
Key opinion leaders explain the use of sublingual apomorphine and trimethobenzamide for Parkinson’s disease.
A panel of experts debate the disadvantages and side effects of apomorphine therapies for Parkinson’s disease.
A discussion on the use of apomorphine subcutaneous injections in managing Parkinson’s disease.
Neurologists debate the use of levodopa inhalation powder in managing Parkinson’s disease.
Physicians discuss when to add on-demand therapies to Parkinson’s disease management.
Key opinion leaders explain the important attributes to consider when choosing an on-demand therapy.
Experts debate the challenges of carbidopa/levodopa, and the relation between levodopa and the gut.
Panelists describe the motor and non-motor symptoms of Parkinson’s disease, linking symptoms to OFF episodes, and how to educate patients.
A discussion on how patients are evaluated for OFF episodes, by expert neurologists.
Physicians explain expected versus unexpected OFF episodes and the use of symptom diaries in managing Parkinson’s disease.
Key opinion leaders provide insight on how OFF episodes affect patients’ quality of life.
Expert neurologists discuss why OFF episodes happen and how soon they occur after starting levodopa.
Panelists have a conversation on the definition of OFF episodes in relation to Parkinson’s disease and how common OFF episodes are for patients.
Published: August 29th 2025 | Updated: September 2nd 2025
Published: July 28th 2025 | Updated: July 30th 2025
Published: May 14th 2025 | Updated: May 16th 2025
Published: May 12th 2025 | Updated: May 13th 2025
Published: March 27th 2025 | Updated: March 28th 2025
Published: March 4th 2025 | Updated: March 19th 2025